Sanofi reveals detailed timeframe for RSV candidate
Now that a new set of study data supports a possible treatment for RSV, Sanofi has laid out its plan for applying to regulatory authorities.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
Over the course of the first six months of 2022, Sanofi expects to submit the first regulatory application for marketing authorization for a possible treatment of respiratory syncytial virus (RSV) in infants.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Three global giants consider vaccine production in Denmark
For subscribers
.jpg&w=384&q=75)
